Recent studies have demonstrated that the overexpression of the c-myc gene in the liver of transgenic mice leads to an increase in both utilization and accumulation of glucose in the liver, suggesting that c-Myc transcription factor is involved in the control of liver carbohydrate metabolism in vivo. To determine whether the increase in c-Myc might control glucose homeostasis, an intraperitoneal glucose tolerance test was performed. Transgenic mice showed lower levels of blood glucose than control animals, indicating that the overexpression of c-Myc led to an increase of blood glucose disposal by the liver. Thus, the increase in c-Myc might counteract diabetic hyperglycemia. In contrast to control mice, transgenic mice treated with streptozotocin showed normalization of concentrations of blood glucose, ketone bodies, triacylglycerols and free fatty acids in the absence of insulin. These findings resulted from the normalization of liver metabolism in these animals. While low glucokinase activity was detected in the liver of diabetic control mice, high levels of both glucokinase mRNA and enzyme activity were noted in the liver of streptozotocin-treated transgenic mice, which led to an increase in intracellular levels of glucose 6-phosphate and glycogen. The liver of these mice also showed an increase in pyruvate kinase activity and lactate production. Furthermore, normalization of both the expression of genes involved in the control ofgluconeogenesis and ketogenesis and the production of glucose and ketone bodies was observed in streptozotocin-treated transgenic mice. Thus, these results suggested that c-Myc counteracted diabetic alterations through its ability to induce hepatic glucose uptake and utilization and to block the activation of gluconeogenesis and ketogenesis.c-myc is part of a gene family encoding nuclear phosphoproteins that can bind to DNA in a sequence-specific manner and act as transcription factors. The c-Myc protein is invoived in the control of cell proliferation, differentiation, neoplasia, apoptosis, and energy metabolism (1-3). This transcription factor recognizes an "E-box" motif with the central consensus sequence CACGTG (1-3), which is also contained in the glucose/carbohydrate regulatory elements located in the promoter of genes coding for some of the enzymes of glycolysis and lipogenesis (4, 5). A glucose-responsive element (GlcRE) was identified in the promoter of the L-pyruvate kinase gene (6-8), which consists of two imperfect E boxes, CACGGG, which differ from the c-Myc family E box by a single nucleotide. This GlcRE is closely related functionally to the carbohydrate response element (ChoRE) described in the S14 and the fatty acid synthase genes, which also contains a c-Myc family E-box motif, CACGTG (9, 10). We have recently shown that an increase in c-Myc protein in liver nuclei of transgenic animals that overexpress c-myc under control of the phosphoenolpyruvate carboxykinase (PEPCK) gene promoter (11) leads to an induction of hepatic glycolysis by increasing bothThe ...